LUMIBIRD |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.45 EUR | +0.81% |
|
-11.07% | +2.22% |
| Apr. 23 | Lumibird: over 7% growth in quarterly sales | CF |
| Mar. 13 | Lumibird: EBITDA improved by 10% in 2023 | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +2.22% | 294M | - | ||
| +7.15% | 217B | B | ||
| +6.60% | 183B | B- | ||
| +9.86% | 131B | B- | ||
| +24.32% | 106B | A- | ||
| -0.95% | 62.16B | A- | ||
| +11.04% | 51.02B | B+ | ||
| +4.81% | 50.89B | B+ | ||
| -1.43% | 40.16B | A | ||
| +24.40% | 31.44B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LBIRD Stock
- Ratings LUMIBIRD
